Q1 2025 EPS Estimates for Apellis Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Zacks Research reduced their Q1 2025 earnings per share estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, April 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.06. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at $0.39 EPS and FY2025 earnings at $1.05 EPS.

A number of other equities research analysts also recently commented on the company. Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Mizuho reiterated a “neutral” rating and set a $60.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. The Goldman Sachs Group lifted their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Oppenheimer lifted their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Trading Down 4.0 %

Apellis Pharmaceuticals stock opened at $47.93 on Thursday. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of -10.70 and a beta of 0.88. The stock has a 50-day moving average price of $58.61 and a 200 day moving average price of $57.37.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. During the same quarter in the previous year, the company posted ($1.50) earnings per share. The company’s revenue was up 545.9% compared to the same quarter last year.

Insider Activity

In other news, CEO Cedric Francois sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $64.11, for a total value of $16,027,500.00. Following the completion of the sale, the chief executive officer now directly owns 313,662 shares in the company, valued at $20,108,870.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Cedric Francois sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the completion of the sale, the chief executive officer now directly owns 313,662 shares in the company, valued at $20,108,870.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The disclosure for this sale can be found here. Insiders sold 381,011 shares of company stock worth $23,463,657 over the last three months. 7.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently made changes to their positions in the company. First Horizon Advisors Inc. increased its position in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after purchasing an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in Apellis Pharmaceuticals during the first quarter worth $29,000. Covestor Ltd boosted its stake in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares during the last quarter. Stephens Consulting LLC acquired a new position in Apellis Pharmaceuticals during the third quarter worth $38,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock worth $115,000 after buying an additional 687 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).